Generic Zidovudine - Retrovir
|
Your reliable supplier of generic medications |
Categories list
AlcoholismAlzheimer's And Parkinson'sAnalgesicsAnti-inflammatoriesAntiallergicAntibioticsAnticonvulsantsAntidepressantsAntifungalsAntiparasiticAntiviralsArthritisAsthmaBirth ControlCancerCardiovascular DiseasesCholesterolDiabetesDiureticsErectile DysfunctionEye CareGastrointestinal TractHIVHypertensionMen's HealthMental DisordersMigraineMuscle RelaxantsNeurological DisordersObesityOsteoporosisRespiratory TractSkin CareSurgeryUrinary TractWomen's Health
Hi.
just want to say thanks for your promt and efficient service.. The tablets arrived well within the timeframe given.. Have passed on your
address, dont know wheather its been used or not..
Best regards... and happy St Patricks from the Irish in France..
- Kieran
Our billing is certified by:
- Lupin, Aurobindo get USFDA nod for HIV drug - Economic Times
Lupin, Aurobindo get USFDA nod for HIV drugEconomic TimesLupin Pharmaceuticals Inc, a subsidiary of Lupin Ltd, has received final approval from US Food and Drug Administration (USFDA) for its generic Lamivudine and Zidovudine combination tablet in strength of 150mg/300 mg, Lupin said in a statement.
- Aurobindo Pharma receives final approval for Lamivudine+Zidovudine Tablets - Equity Bulls
Zee NewsAurobindo Pharma receives final approval for Lamivudine+Zidovudine TabletsEquity BullsAurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market for Lamivudine & Zidovudine tablets USP 150/300 mg (ANDA 202418) and is ready for launch.
- Lupin, Aurobindo get USFDA nod for HIV drug - Zee News
Zee NewsLupin, Aurobindo get USFDA nod for HIV drugZee NewsZidovudine combination tablet in strength of 150mg/300 mg, Lupin said in a statement.
- Aurobindo Pharma receives US FDA approval - Express Pharma
Aurobindo Pharma receives US FDA approvalExpress PharmaAurobindo Pharma has received final approval from the US FDA to manufacture and market Lamivudine and Zidovudine tablets USP 150/300 mg (ANDA 202418) and is ready for launch.
- LANDMARK HIV DRUG'S PATENT EXPIRES TODAY - U-T San Diego
LANDMARK HIV DRUG'S PATENT EXPIRES TODAYU-T San DiegoThe FDA approved Combivir (lamivudine/zidovudine) in 1997, greatly changing the treatment of HIV/AIDS.
Copyright © www.bestbuy-pharmacy.com is an affiliate marketing website. All rights reserved.